Recaticimab (SHR-1209) is a humanized monoclonal antibody that is orally active and selectively targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9 with high affinity, Recaticimab effectively increases the expression of low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, subsequently leading to a reduction in plasma low-density lipoprotein cholesterol (LDL-C) levels. This antibody is particularly valuable for research focused on hypercholesterolemia and hyperlipidemia, offering a promising tool for investigating the regulation and management of cholesterol levels.
Recaticimab (SHR-1209) is a humanized monoclonal antibody that is orally active and selectively targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9 with high affinity, Recaticimab effectively increases the expression of low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, subsequently leading to a reduction in plasma low-density lipoprotein cholesterol (LDL-C) levels. This antibody is particularly valuable for research focused on hypercholesterolemia and hyperlipidemia, offering a promising tool for investigating the regulation and management of cholesterol levels.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
